NUCLEOLIN and central nervous system cancer: NCL showed a significant upregulation from low-grade (WHO grade I and II) to high-grade glioma (WHO grade III) as well as a significant increase from WHO grade III to WHO grade IV glioma (Figure 2, A–D, and F).